Core 2 biomarkers (MTBR-tau243, p-tau205 non-phosphorylated mid-region tau fragments, and Tau PET) become abnormal later in the evolution of AD and inform on the risk of short-term progression in people without symptoms. Here, MAPT is linked to Alzheimer disease.